A large global specialty pharmaceutical company has multiple long-term rare disease registries that were running on a variety of older EDC technologies. These registries each play a vital role in the ongoing safety and efficacy assessment for these transformative drug therapies – each drug having critical life-sustaining significance for their relatively small population of patients.

​Download this case study to learn how one pharmaceutical company:

• Overcame the challenge of data quality, patient privacy and site satisfaction utilizing several different legacy EDC platforms.
• Solved for unmet reporting requirements.
• Took control by implementing a robust system partnering with a customer-first solution provider.